Intra-vitreal of bevacizumab
Phase 2Monoclonal antibody
Intra-vitreal of bevacizumab is one of 14 small molecule programs targeting Anterior Ischemic Optic Neuropathy. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Anterior Ischemic Optic Neuropathy
#DrugCompanyPhaseTrials
1Tracleer
Johnson & JohnsonApproved
Ampyra
MMerz Pharmaceuticals GmbH
Approved
Caverject
VViatris Specialty LLC
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Kenalog
BBassett Healthcare
Approved
Medrol
PfizerPhase 3
Levodopa-Carbidopa
AbbVieApproved
Citicoline
UUniversity of Texas Southwestern Medical Center
Approved
Avastin
BBio-Thera Solutions
Phase 2
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- MMount Sinai Hospital, Canada